On Friday, Shares of Oncothyreon Inc (USA) (NASDAQ:ONTY), lost - 0.43% to $2.34.
UltimateStockAlerts.com is an exclusively NASDAQ & NYSE stock alert service focused on day and swing trading. Recently we are taking a look at four companies which we believe could provide investors with noteworthy down side/upside over the course of the next few trading sessions.
Oncothyreon Inc. (ONTY) opened yesterday’s session at 2.29 bettering the previous close of 2.13. The strong start was a relief for some investors who no doubt felt the brunt of the confusion which erupted over data released by the company in the sessions prior. ONTY released data on its ongoing trials testing ONT-380 in patients with breast cancer. In the end investors and analysts seemed to have made sense of the data because ONTY went on to post a high of 2.48 on better than average volume of 3.8M shares. ONTY closed the day at 2.35 which confirmed the bullish turnaround, ensuing current momentum. We will continue to monitor ONTY and will alert our newsletter subscribers when a gain opportunity presents itself.
Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates comprise ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, counting breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, in addition to certain types of lung cancer.
Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), declined -5.91% to $9.08, during its last trading session.
ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, declared that it will host a conference call and webcast slide presentation on Wednesday, December 16, 2015 at 4:30 PM ET to provide a corporate update and discuss the Company’s 2016 outlook.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
Finally, KB Home (NYSE:KBH), ended its last trade with - 1.46% loss, and closed at $12.80.
KB Home, declared the grand opening of Artero in Livermore, a 58-unit townhome community conveniently located near major freeways, employers and the city’s historic downtown district.
Artero is close to Interstate 580 for easy commuting to employment centers in Pleasanton, San Ramon and throughout the East Bay, in addition to to two ACE train stations for direct connections into the heart of the Silicon Valley. A hub for science and technology, Livermore is home to the renowned Lawrence Livermore and Sandia National Laboratories, and offers a broad range of cultural and recreational attractions, counting a thriving arts scene, rich western heritage and vibrant wine industry.
Residents at Artero can enjoy the community’s charming neighborhood atmosphere, while living less than three miles from Livermore’s historic downtown area and its world-class shopping, dining and entertainment. Artero homeowners can also take advantage of the community’s close proximity to the popular San Francisco Premium Outlets®.
KB Home operates as a homebuilding company in the United States. It constructs and sells various homes, counting attached and detached single-family residential homes, townhomes, and condominiums primarily for first-time, move-up, and active adult homebuyers under the name KB Home.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.